{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-102004","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.436224+00:00","generated_at":"2026-05-17T02:21:19.745967+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aprea reports 3 of 4 patients with stable disease at 100 mg APR-1051 in Phase 1 trial","bullets":["3 of 4 heavily pretreated patients achieved stable disease (RECIST v1.1) at 100 mg dose level.","Disease stabilization observed in tumors with FBXW7, CCNE1, KRAS G12V, TP53 mutations.","No dose-limiting toxicities reported; dose escalation continues at 150 mg cohort.","Poster presented at AACR-NCI-EORTC conference on Oct 24, 2025; data cutoff Sep 17, 2025.","Individual responses: rectal cancer patient on 145 days of treatment with -13% reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-102004","json":"https://secwatch.observer/filing/0001104659-25-102004.json","markdown":"https://secwatch.observer/filing/0001104659-25-102004.md","text":"https://secwatch.observer/filing/0001104659-25-102004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925102004/0001104659-25-102004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925102004/apre-20251024x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:21:19.745967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}